NAD+ vs Niagen: Research Literature Comparison
Two compounds, two separate research records. This reference sets NAD+ and Niagen against each other on parameters a laboratory can independently verify.
Compound profiles
NAD+ in the indexed record
The literature on NAD+ is an extensive body of work: 76,583 PubMed-indexed records, alongside 749 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
Niagen in the indexed record
The literature on Niagen is a limited body of work: 18 PubMed-indexed records, alongside 49 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Cell Metab, EClinicalMedicine, Hum Exp Toxicol, spanning 2016–2025.
- Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults — Sci Rep, 2019. PMID: 31278280
- Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial — EClinicalMedicine, 2025. PMID: 41357333
- Safety assessment of nicotinamide riboside, a form of vitamin B(3) — Hum Exp Toxicol, 2016. PMID: 26791540
- Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia — Mov Disord, 2024. PMID: 37899683
Side-by-side research profile
| Parameter | NAD+ | Niagen |
|---|---|---|
| PubMed indexed records | 76,583 | 18 |
| Registered studies (ClinicalTrials.gov) | 749 | 49 |
| Literature depth | Extensive | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
NAD+ and Niagen sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for NAD+ describes conditions validated for NAD+: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Niagen without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. NAD+ carries 76,565 more indexed records than Niagen, which means published methodology, characterisation data and replication attempts are more readily located for NAD+. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (749 vs 49) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Selecting between them for a study design
NAD+ and Niagen are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (NAD+) generally offers more methodological precedent.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are NAD+ and Niagen the same compound?
No. They are structurally distinct research compounds with separate literature records — 76,583 indexed records for NAD+ and 18 for Niagen.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.